JP2021526525A5 - - Google Patents

Info

Publication number
JP2021526525A5
JP2021526525A5 JP2020566845A JP2020566845A JP2021526525A5 JP 2021526525 A5 JP2021526525 A5 JP 2021526525A5 JP 2020566845 A JP2020566845 A JP 2020566845A JP 2020566845 A JP2020566845 A JP 2020566845A JP 2021526525 A5 JP2021526525 A5 JP 2021526525A5
Authority
JP
Japan
Prior art keywords
dose
adc
here
patient
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054748 external-priority patent/WO2019234694A2/en
Publication of JP2021526525A publication Critical patent/JP2021526525A/ja
Publication of JP2021526525A5 publication Critical patent/JP2021526525A5/ja
Priority to JP2024095931A priority Critical patent/JP2024154433A/ja
Pending legal-status Critical Current

Links

JP2020566845A 2018-06-07 2019-06-07 抗体薬物コンジュゲート(adcs)を用いた治療方法 Pending JP2021526525A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024095931A JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート(adcs)を用いた治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862682154P 2018-06-07 2018-06-07
US62/682,154 2018-06-07
US201962841702P 2019-05-01 2019-05-01
US62/841,702 2019-05-01
PCT/IB2019/054748 WO2019234694A2 (en) 2018-06-07 2019-06-07 Therapeutic methods using antibody drug conjugates (adcs)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024095931A Division JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート(adcs)を用いた治療方法

Publications (2)

Publication Number Publication Date
JP2021526525A JP2021526525A (ja) 2021-10-07
JP2021526525A5 true JP2021526525A5 (cg-RX-API-DMAC7.html) 2022-06-14

Family

ID=68769968

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566845A Pending JP2021526525A (ja) 2018-06-07 2019-06-07 抗体薬物コンジュゲート(adcs)を用いた治療方法
JP2024095931A Pending JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート(adcs)を用いた治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024095931A Pending JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート(adcs)を用いた治療方法

Country Status (7)

Country Link
US (2) US20210283267A1 (cg-RX-API-DMAC7.html)
EP (1) EP3801635A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021526525A (cg-RX-API-DMAC7.html)
CN (1) CN112566671A (cg-RX-API-DMAC7.html)
AU (1) AU2019283654A1 (cg-RX-API-DMAC7.html)
CA (1) CA3101943A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019234694A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
JP2022529727A (ja) * 2019-04-24 2022-06-23 マジェンタ セラピューティクス インコーポレイテッド Anti-cd117 とその使用
WO2020219778A2 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
JP2022530442A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド アントラサイクリン抗体薬物複合体およびその使用
JP2022530438A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド 抗cd117抗体薬物複合体およびその使用
GB202004263D0 (en) * 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080080482A (ko) * 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 eph 수용체 항체
PL2099823T5 (pl) * 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
ES2945588T3 (es) * 2014-08-26 2023-07-04 Univ Leland Stanford Junior Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora
ES2826566T3 (es) * 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
HK1256681A1 (zh) * 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
AU2016258988A1 (en) * 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
US10464969B2 (en) * 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
US10111966B2 (en) * 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
CN117653740A (zh) * 2016-12-21 2024-03-08 诺华股份有限公司 用于消融造血干细胞的抗体药物缀合物
JP2020519640A (ja) * 2017-05-17 2020-07-02 イミュノジェン, インコーポレイテッド 抗cd33イムノコンジュゲート投与計画

Similar Documents

Publication Publication Date Title
AU2021225125B9 (en) Antibody drug conjugate loaded with binary toxins and its application
AU2019455069B2 (en) A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
JP5314590B2 (ja) カンプトテシン結合部分
ES2941520T3 (es) Compuestos de 1H-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (TLR7) y métodos y usos para los mismos
TWI362934B (en) Phosphonate analogs of hiv inhibitor compounds
JP2020506176A5 (cg-RX-API-DMAC7.html)
US20230295346A1 (en) Prodruggable antibodies, prodrugs thereof, and methods of use and making
JP2022512778A5 (cg-RX-API-DMAC7.html)
HUE027549T2 (hu) Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére
KR20220147719A (ko) 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
JP2010516675A (ja) 治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分
JP2018509394A5 (cg-RX-API-DMAC7.html)
CA3253667A1 (en) ANTIBODY-DRUG CONJUGATE, RELATED PHARMACEUTICAL COMPOSITION AND RELATED USE
RS62860B1 (sr) Citotoksična i antimitotička jedinjenja, i postupci upotrebe istih
CN117157098A (zh) 一种药物组合及其用途
US20230181743A1 (en) Functional lipid derivatives and uses thereof
TW202432559A (zh) 一類連接子藥物及其抗體-藥物偶聯物的製備方法和應用
Takeuchi et al. Effects of bleomycin on mouse transplantable tumors
EA022408B1 (ru) Производные санглиферина и способы их получения
CN1817866A (zh) 一组连有核苷碱基的格尔德霉素衍生物
WO2000067792A1 (fr) Anticorps monoclonal dirige contre les cellules de carcinome renal humain
CN115944629A (zh) 雷帕霉素在治疗或预防乙型肝炎中的应用
US11717540B2 (en) Modified immune cells and uses thereof
RU2795148C2 (ru) Конъюгат антитело-лекарственное средство, нагруженный бинарными токсинами, и его применение
HK40085783A (en) Antibody drug conjugate loaded with double toxins and application thereof